This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Written by Dr. Parmis Mojarab, DO·Reviewed by Jonathan Snipes, MD·Published July 12, 2026·Last reviewed July 12, 2026·Methodology v1.0

Tirzepatide: uses, evidence, cost and safety

Q: What are the most common side effects of Tirzepatide?

Gastrointestinal effects dominate — nausea, diarrhea, vomiting, constipation — and are most pronounced during titration. Serious but less common risks mirror the GLP-1 class: pancreatitis, gallbladder disease and injection-site reactions.

Q: Who should not take Tirzepatide?

Boxed warning for thyroid C-cell tumors based on rodent data; contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Not for use in pregnancy. May reduce the effectiveness of oral contraceptives around dose changes.

Quick answer

Tirzepatide is a dual GIP and GLP-1 receptor agonist — it activates two incretin receptors rather than one. It is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. In the pivotal SURMOUNT-1 trial, the highest dose produced about 20.9% average body-weight reduction over 72 weeks.

What Tirzepatide is

Tirzepatide is a dual gip / glp-1 receptor agonist. It is marketed as Mounjaro (type 2 diabetes), Zepbound (chronic weight management). Tirzepatide is a dual GIP and GLP-1 receptor agonist — it activates two incretin receptors rather than one. It is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. In the pivotal SURMOUNT-1 trial, the highest dose produced about 20.9% average body-weight reduction over 72 weeks.

Regulatory status

FDA-approved as a finished drug under the brand names Mounjaro and Zepbound.

How it works

Tirzepatide activates both the GIP and GLP-1 receptors. The dual mechanism is associated with larger average weight reduction than single GLP-1 agonism in head-to-head diabetes trials, though individual response varies widely.

Clinical evidence

Average body-weight reduction in pivotal trials — Tirzepatide

Mean percent body-weight change from controlled trials. Bars show trial averages over the study period; individual results vary widely and are not guaranteed. Values shown are percentage points.

The SURMOUNT program (weight management) and SURPASS program (type 2 diabetes) are the pivotal randomized trials. SURMOUNT-1 reported mean reductions of roughly 15% to 21% across the 5 mg to 15 mg doses. SURPASS-2 compared tirzepatide directly against semaglutide 1 mg in type 2 diabetes and favored tirzepatide on A1c and weight endpoints.

Pivotal trial evidence — mean body-weight change, with citations
Trial	Arm	Result	Duration	Comparator	Source
SURMOUNT-1	Tirzepatide 15 mg	−20.9%	72 weeks	Placebo −3.1%	NEJM 2022 (Jastreboff et al.)
SURMOUNT-1	Tirzepatide 10 mg	−19.5%	72 weeks		NEJM 2022
SURMOUNT-1	Tirzepatide 5 mg	−15.0%	72 weeks		NEJM 2022
SURMOUNT-5	Tirzepatide (max tolerated)	−20.2%	72 weeks	vs semaglutide −13.7%	NEJM 2025 (Aronne et al.)
STEP 1	Semaglutide 2.4 mg	−14.9%	68 weeks	Placebo −2.4%	NEJM 2021 (Wilding et al.)
STEP 8	Semaglutide 2.4 mg	−15.8%	68 weeks	vs liraglutide 3.0 mg −6.4%	JAMA 2022 (Rubino et al.)
SCALE	Liraglutide 3.0 mg	−8.0%	56 weeks	Placebo −2.6%	NEJM 2015
SELECT	Semaglutide 2.4 mg	20% MACE reduction	~40 months	Cardiovascular outcomes	NEJM 2023

The head-to-head trial: SURMOUNT-5

SURMOUNT-5 head-to-head: mean body-weight change at 72 weeks

Aronne LJ et al., New England Journal of Medicine, May 11, 2025. NCT05822830. Open-label, Lilly-funded — see caveats below.

Design. Phase 3b, open-label, randomized head-to-head. 751 adults with obesity (BMI ≥30, or ≥27 with a weight-related comorbidity) and without type 2 diabetes, randomized 1:1 to maximum tolerated tirzepatide (10 or 15 mg) versus maximum tolerated semaglutide (1.7 or 2.4 mg), once weekly for 72 weeks.

Result. Least-squares mean body-weight change at week 72: −20.2% with tirzepatide (95% CI −21.4 to −19.1) versus −13.7% with semaglutide (95% CI −14.9 to −12.6), p<0.001 — about 47% greater relative weight loss, or 22.8 kg versus 15.0 kg. Tirzepatide was superior on the primary endpoint and all five key secondary endpoints. 31.6% of tirzepatide patients lost at least 25% of body weight, versus 16.1% on semaglutide.

Caveats that belong with the numberTwo caveats matter. The trial was open-label — patients and investigators knew which drug they were getting — and it was funded by Eli Lilly, which makes tirzepatide. The result is consistent with the separate SURMOUNT and STEP programmes, which is the main reason to take it seriously, but neither caveat should be dropped when the number is quoted.

Source: Aronne LJ et al., New England Journal of Medicine, May 11, 2025. NCT05822830.

Dosing and titration

Tirzepatide label titration schedule
Period	Dose	Note
Weeks 1–4	2.5 mg	Starting dose. Not intended for weight loss — this is a tolerance-building dose.
Weeks 5–8	5 mg	First therapeutic dose.
Weeks 9–12	7.5 mg	Escalate only if tolerated.
Weeks 13–16	10 mg	A common maintenance dose.
Weeks 17–20	12.5 mg	Escalate only if tolerated.
Week 21+	15 mg	Maximum maintenance dose.

Why titration decides your real priceDose escalation is not a formality — it is where cost and side effects are actually decided. Two consequences follow that most pricing pages ignore.

1. The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose that is not intended to produce weight loss. Ask what you will pay at 10 mg, and compare that number.

2. A "microdose" of roughly 1 mg/week sits below every dose studied in SURMOUNT. The trials that established tirzepatide's efficacy used 5, 10 and 15 mg. A 1 mg microdose is not a discounted version of that result; it is a different product with a smaller expected effect and no equivalent trial evidence behind it.

Reading trial numbersWeight-loss figures come from controlled trials in specific populations over defined periods. Individual results vary widely, and trial averages are not a promise of outcome.

Common and serious side effects

Gastrointestinal effects dominate — nausea, diarrhea, vomiting, constipation — and are most pronounced during titration. Serious but less common risks mirror the GLP-1 class: pancreatitis, gallbladder disease and injection-site reactions.

Warnings and contraindications

Boxed warning for thyroid C-cell tumors based on rodent data; contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Not for use in pregnancy. May reduce the effectiveness of oral contraceptives around dose changes.

When to seek urgent careSeek urgent care for severe abdominal pain (possible pancreatitis), signs of an allergic reaction, or symptoms of gallbladder disease. Telehealth is not a substitute for emergency care.

Brand versus compounded tirzepatide

Tirzepatide is sold as an FDA-approved brand drug (Mounjaro (type 2 diabetes), Zepbound (chronic weight management)) and, separately, as a compounded preparation through some telehealth programs. These are not regulatory equals.

What the FDA actually saysCompounded drugs are <b>not FDA-approved</b>: the agency does not review them for safety, effectiveness or quality before they are marketed. Federal law also bars compounding drugs that are <b>essentially a copy</b> of a commercially available approved product — a bar that is lifted only while the drug is on the FDA shortage list. Both shortages are over. The FDA declared the tirzepatide shortage resolved on October 2, 2024 and the semaglutide shortage resolved on February 21, 2025, and enforcement discretion ended for all compounders between February 18 and May 22, 2025. On April 30, 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list on a finding of no clinical need. Routine compounding of these molecules is therefore no longer lawful on the basis that made the market — a fact most comparison sites still describe as "permanent legitimacy." It is not.

We deliberately avoid the claim, common on competitor sites, that a compounded product's "safety profile mirrors" the brand. The molecule may be identical; the regulatory oversight, quality verification and manufacturing controls are not.

The finding most comparison sites will not printThe economic case for compounded GLP-1 has narrowed sharply, and almost no comparison site says so. In 2023 the choice was roughly $1,000+/month for brand versus $150–$300 for compounded — a gap wide enough to justify real regulatory risk. As of July 12, 2026, brand Zepbound is $299–$449 through LillyDirect, brand Wegovy is $349 (or $149 for the oral tablet) through NovoCare, and both drop to roughly $25 with commercial coverage. Meanwhile compounded programs advertise $99–$299.

For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.

Brand vs compounded — monthly cost, verified July 12, 2026

Brand figures are verified against manufacturer pricing pages. The compounded figure is the lowest advertised rate we have seen and is unverified. Note where the brand oral tablet sits.

For how to evaluate a compounding program, see how to verify a compounding pharmacy.

Frequently asked questions

Is Tirzepatide FDA-approved?

FDA-approved as a finished drug under the brand names Mounjaro and Zepbound.

How does Tirzepatide work?

What are the most common side effects of Tirzepatide?

Who should not take Tirzepatide?

Is compounded Tirzepatide the same as the brand version?

The active ingredient is the same molecule. However, compounded versions are not FDA-approved, the FDA does not verify their quality before marketing, and after the shortage resolved, routine compounding of this molecule became restricted. See our compounded tirzepatide guide.

Sources

U.S. Food and Drug Administration — prescribing information and drug labels for Mounjaro (type 2 diabetes), Zepbound (chronic weight management).
Pivotal randomized controlled trials as cited in the evidence section (SURMOUNT, SURPASS, STEP, SUSTAIN, SCALE as applicable).
CMS National Plan & Provider Enumeration System — clinician verification for reviewed providers.
ClinicalTrials.gov — trial registrations for investigational agents.

Spotted an error? Submit a correction.